Manas AI, a full-stack, AI-native drug discovery and development company, has announced a strategic partnership with Schrödinger, Inc., gaining deep, exclusive access to Schrödinger’s advanced physics-based computational platform. This collaboration positions Manas AI at the forefront of next-generation AI-driven molecular discovery. The agreement enables Manas AI to leverage Schrödinger’s industry-leading technology, which combines quantum mechanics, molecular dynamics, and machine learning to simulate and predict the behavior of molecules with high accuracy. By integrating this physics-informed approach into its own AI systems, Manas AI is developing a first-of-its-kind, physics-based atomic "world model"—an AI-powered framework designed to simulate molecular interactions at the most fundamental level. This world model aims to serve as an intelligent, predictive oracle for drug discovery, capable of guiding the design of novel therapeutics with unprecedented precision and speed. Unlike purely data-driven models, Manas AI’s approach embeds physical laws directly into its AI architecture, enabling more reliable extrapolation and reduced reliance on large datasets. The partnership underscores Manas AI’s commitment to building a robust, scientifically grounded foundation for its AI platform, differentiating it from other generative drug discovery companies that rely primarily on pattern recognition. By combining the power of physics-based simulation with cutting-edge artificial intelligence, Manas AI is advancing a new paradigm in how drugs are discovered and developed. The collaboration with Schrödinger is expected to accelerate Manas AI’s pipeline of novel drug candidates across multiple therapeutic areas, particularly in complex diseases where traditional methods have struggled. The company plans to use the platform to explore new chemical spaces, optimize lead compounds, and predict biological outcomes with higher confidence. This strategic integration marks a significant milestone in Manas AI’s mission to transform drug discovery by merging deep scientific principles with the scalability and speed of AI. As the company continues to scale its platform, the partnership with Schrödinger is expected to play a central role in driving innovation and delivering real-world impact in medicine.